Key Highlights

  • Sagimet Biosciences Inc. (NASDAQ:SGMT) priced an underwritten offering of 8,750,010 Series A shares at USD 10.00 and pre-funded warrants for 2,750,010 shares at USD 9.9999 on September 30, 2026, for gross proceeds of about USD 115.0 million.
  • The price was about a 7% premium to the prior close, simple arithmetic on the 7.18% pre-market gain at USD 10.00, and shares traded as high as USD 10.92 during the session before pulling back.
  • The company also reported 52-week data from a Phase 3 trial of denifanstat in moderate to severe acne, saying participants tolerated it well with no drug-related serious adverse events.
  • Commodore Capital led the financing with RA Capital, BVF Partners, Columbia Threadneedle, Woodline and others, and closing is expected on October 1.

The Offering

Sagimet Biosciences Inc. (NASDAQ:SGMT) is selling all securities itself. The 8,750,010 shares and 2,750,010 pre-funded warrants total about 11.5 million shares, which at USD 10 equals the USD 115.0 million raise. Pre-funded warrants are exercisable immediately for USD 0.0001, which lets large holders stay under ownership caps. Joint bookrunners were Leerink Partners, TD Cowen, Guggenheim Securities and Oppenheimer. Proceeds will fund a Phase 3 acne trial, pre-launch work for denifanstat, TVB-3567 through Phase 2 results and a topical program to IND filing. The stock closed Tuesday down 6.14%, so USD 10.00 was a premium.

The Data and the Drug

Denifanstat is an oral, once-daily inhibitor of fatty acid synthase, an enzyme involved in oil production in the skin. The company reported 52-week Phase 3 data in moderate to severe acne and said the medicine was well tolerated for a year, with no drug-related serious adverse events or permanent discontinuations. Positive long-term data supports the plan for a US Phase 3 trial of about 800 patients. Sagimet raised USD 175 million in April at USD 6.00 per share, so the new price is about 67% higher, simple arithmetic. Analysts say the stock holds well above its 52-week low of USD 4.50, even with new shares coming. Shares rose as much as 8.6% to USD 10.13 in one snapshot. Sagimet Biosciences Inc. (NASDAQ:SGMT) has a Market Value near USD 580 million.

Dilution and Risks

Equity raises dilute holders, and about 11.5 million new shares and warrants are material for a company of this size. Clinical risk remains: results from earlier trials may not replicate in a US population, regulators will weigh long-term safety, and acne treatments face established competition from topical, oral and injectable options. Analysts lean positive, with nine Buy ratings, one Hold and two Sell. The pricing at a premium suggests strong demand, but a stock that rallies into an offering can retrace. Investors should watch the closing, the Phase 3 start and the cash runway. Sagimet Biosciences Inc. (NASDAQ:SGMT) now has more cash to reach key readouts.

Where Things Stand

The biotech is Sagimet, and it priced a USD 115 million raise at a premium on the same day it reported positive 52-week Phase 3 acne data because investors were willing to fund a pivotal program. Sagimet Biosciences Inc. (NASDAQ:SGMT) takes dilution in exchange for runway to run a pivotal US program and prepare for launch. The balance of evidence is constructive, with US trial risk and the usual dilution drag ahead of it. The next catalysts are the October 1 closing, the US Phase 3 start and TVB-3567 results.